

Použitá literatura

1. Huser M, Crha I, Žáková J, Ventruba P: Proces reprodukčního stárnutí ženy – jeho příčiny a možnosti ovlivnění v praxi [Process of women's reproductive ageing – causes, evaluation and possible clinical usage]. *Čes Gynekol* 2010; 75(4): 353–358.
2. Němec P, Huser M, Souček M: Možnosti ochrany reprodukčních funkcí u žen podstupujících léčbu cytotoxickými léky [The options for preserving reproductive functions in women undergoing cytostatic therapy]. *Vnitř Lék* 2008; 54(3): 245–250.
3. Crha I, Ventruba P, Žáková J et al.: Survival and infertility treatment in male cancer patients after sperm banking. *Fertil Steril* 2009; 91(6): 2344–2348.
4. Woodruff TK: The Oncofertility Consortium – addressing fertility in young people with cancer. *Nat Rev Clin Oncol* 2010; 7(8): 466–475.
5. Faddy MJ, Gosden RG, Gougeon A et al.: Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. *Hum Reprod* 1992; 7(10): 1342–1346.
6. Gougeon A, Chainy GB: Morphometric studies of small follicles in ovaries of women at different ages. *J Reprod Fertil* 1987; 81(2): 433–442.
7. Block E: Quantitative morphological investigations of the follicular system in women; variations at different ages. *Acta Anat* 1952; 14(1–2): 108–123.
8. Faddy MJ, Gosden RG: A mathematical model of follicle dynamics in the human ovary. *Hum Reprod Oxf Engl* 1995; 10(4): 770–775.
9. Caulden ME: Maternal age effect: the enigma of Down syndrome and other trisomic conditions. *Mutat Res* 1992; 296(1–2): 69–88.
10. De Bruin JP, Dorland M, Spek ER et al.: Age-related changes in the ultrastructure of the resting follicle pool in human ovaries. *Biol Reprod* 2004; 70(2): 419–424.
11. Kitagawa T, Suganuma N, Nawa A et al.: Rapid accumulation of deleted mitochondrial deoxyribonucleic acid in postmenopausal ovaries. *Biol Reprod* 1993; 49(4): 730–736.
12. Sauer MV: The impact of age on reproductive potential: lessons learned from oocyte donation. *Maturitas* 1998; 30(2): 221–225.
13. Takai Y, Canning J, Perez GI et al.: Bax, caspase-2, and caspase-3 are required for ovarian follicle loss caused by 4-vinylcyclohexene diepoxide exposure of female mice in vivo. *Endocrinology* 2003; 144(1): 69–74.
14. Rucker EB 3rd, Dierisseau P, Wagner KU et al.: Bcl-x and Bax regulate mouse primordial germ cell survival and apoptosis during embryogenesis. *Mol Endocrinol* 2000; 14(7): 1038–1052.
15. Kolesnick RN, Krönke M: Regulation of ceramide production and apoptosis. *Annu Rev Physiol* 1998; 60: 643–665.
16. Olivera A, Kohama T, Edsall L et al.: Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. *J Cell Biol* 1999; 147(3): 545–558.
17. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL: Germline stem cells and follicular renewal in the postnatal mammalian ovary. *Nature* 2004; 428(6979): 145–150.
18. Oktay K: Spontaneous conceptions and live birth after heterotopic ovarian transplantation: is there a germline stem cell connection? *Hum Reprod Oxf Engl* 2006; 21(6): 1345–1348.
19. Goldenberg RL, Culhane JF: Low birth weight in the United States. *Am J Clin Nutr* 2007; 85(2): 584S–590S.
20. Westhoff C, Murphy P, Heller D. Predictors of ovarian follicle number. *Fertil Steril* 2000; 74(4): 624–628.

21. de Bruin JP, Bovenhuis H, van Noord PAH et al.: The role of genetic factors in age at natural menopause. *Hum Reprod* 2001; 16(9): 2014–2018.
22. Cibula D, Henzl MR, Živný J: *Základy gynekologické endokrinologie*. Grada Publishing, Praha, 2002.
23. Rebar RW: Premature ovarian failure. *Obstet Gynecol* 2009; 113(6): 1355–1363.
24. Sills ES, Alper MM, Walsh APH: Ovarian reserve screening in infertility: practical applications and theoretical directions for research. *Eur J Obstet Gynecol Reprod Biol* 2009; 146(1): 30–36.
25. Broekmans FJ, Kwee J, Hendriks DJ et al.: A systematic review of tests predicting ovarian reserve and IVF outcome. *Hum Reprod Update* 2006; 12(6): 685–718.
26. Kwee J, Elting ME, Schats R et al.: Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. *Reprod Biol Endocrinol* 2007; 5: 9.
27. Hendriks DJ, Kwee J, Mol BWJ et al.: Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. *Fertil Steril* 2007; 87(4): 764–775.
28. Hugues JN, Theron-Gerard L, Coussieu C et al.: Assessment of theca cell function prior to controlled ovarian stimulation: the predictive value of serum basal/stimulated steroid levels. *Hum Reprod Oxf Engl* 2010; 25(1): 228–234.
29. Wallace WH, Kelsey TW: Human ovarian reserve from conception to the menopause. *PLoS ONE* 2010; 5(1): e8772.
30. Cook CL, Siow Y, Taylor S, Fallat ME: Serum Müllerian-inhibiting substance levels during normal menstrual cycles. *Fertil Steril* 2000; 73(4): 859–861.
31. La Marca A, Sighinolfi G, Radi D et al.: Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). *Hum Reprod Update* 2010; 16(2): 113–130.
32. Nelson SM, Messow MC, McConnachie A et al.: External validation of nomogram for the decline in serum anti-Müllerian hormone in women: a population study of 15,834 infertility patients. *Reprod Biomed Online* 2011; 23(2): 204–206.
33. Hagen CP, Aksglaede L, Sørensen K et al.: Serum levels of anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. *J Clin Endocrinol Metab* 2010; 95(11): 5003–5010.
34. Kelsey TW, Wright P, Nelson SM et al.: A validated model of serum anti-Müllerian hormone from conception to menopause. *PLoS One* 2011; 6(7): e22024.
35. Ústav zdravotnických informací a statistiky České republiky: Cancer incidence in the Czech Republic. *Zdr Stat* 2010.
36. Dreifaldt AC, Carlberg M, Hardell L: Increasing incidence rates of childhood malignant diseases in Sweden during the period 1960–1998. *Eur J Cancer* 2004; 40(9): 1351–1360.
37. Stewart BW, Kleihues P: *World Cancer Report*. IARC Press, 2008.
38. Barr RD, Clark DA, Booth JD: Dyspermia in men with localized Hodgkin's disease. A potentially reversible, immune-mediated disorder. *Med Hypotheses* 1993; 40(3): 165–168.
39. Spermon JR, Kiemeny LA, Meuleman EJ et al: Fertility in men with testicular germ cell tumors. *Fertil Steril* 2003; 79, suppl. 3: 1543–1549.
40. Howell SJ, Shalet SM: Testicular function following chemotherapy. *Hum Reprod Update* 2001; 7(4): 363–369.
41. Bath LE, Critchley HO, Chambers SE et al.: Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. *Br J Obstet Gynaecol* 1999; 106(12): 1265–1272.

42. Sudour H, Chastagner P, Claude L et al.: Fertility and pregnancy outcome after abdominal irradiation that included or excluded the pelvis in childhood tumor survivors. *Int J Radiat Oncol Biol Phys* 2010; 76(3): 867-873.
43. Schrader M, Heicappell R, Müller M et al.: Impact of chemotherapy on male fertility. *Onkologie* 2001; 24(4): 326-330.
44. Loren AW et al.: Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients. *Bone Marrow Transplant* 2013; 48(8): 1091-1097.
45. Hulvat MC, Jeruss JS: Maintaining fertility in young women with breast cancer. *Curr Treat Options Oncol* 2009; 10(5-6): 308-317.
46. Lower EE, Blau R, Gazder P, Tummala R: The risk of premature menopause induced by chemotherapy for early breast cancer. *J Womens Health Gen Based Med* 1999; 8(7): 949-954.
47. Behringer K, Thielen I, Mueller H et al.: Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. *Ann Oncol* 2012; 23(7): 1818-1825.
48. Bokemeyer C, Schmoll HJ, van Rhee J et al.: Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. *Ann Hematol* 1994; 68(3): 105-110.
49. Meirov D: Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. *Leuk Lymphoma* 1999; 33(1-2): 65-76.
50. Chiarelli AM, Marrett LD, Darlington G: Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada. *Am J Epidemiol* 1999; 150(3): 245-254.
51. Meirov D, Levron J, Eldar-Geva T et al.: Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. *N Engl J Med* 2005; 353(3): 318-321.
52. Hawkins MM. Pregnancy outcome and offspring after childhood cancer. *BMJ* 1994; 309(6961): 1034.
53. Grigg AP, McLachlan R, Zaja J, Szer J: Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). *Bone Marrow Transplant* 2000; 26(10): 1089-1095.
54. Green DM, Whitton JA, Stovall M et al.: Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *Am J Obstet Gynecol* 2002; 187(4): 1070-1080.
55. Marks DI, Friedman SH, Delli Carpini L et al.: A prospective study of the effects of high-dose chemotherapy and bone marrow transplantation on sexual function in the first year after transplant. *Bone Marrow Transplant* 1997; 19(8): 819-822.
56. Ventruba P, Pilka L, Čupr Z et al.: Development and results of microsurgical sterility operations at the Gynecology and Obstetrics Clinics of the Brno Masaryk University. *Zentralblatt Für Gynäkol* 1991; 113(10): 549-556.
57. Crha I, Ventruba P, Mardešić T, Žáková J: Dárcovství gamet - biologické, legislativní a etické aspekty [Gamete donation - biological, legislative and ethical aspects]. *Čes Gynkol* 1997; 62(2): 72-75.
58. Crha I, Dostál J, Ventruba P a kol.: Etické a legislativní otázky odběru a užití spermií zemřelého [Posthumous sperm procurement and use - ethical and legal dilemmas]. *Čes Gynkol* 2004; 69(4): 335-339.
59. Dostál J, Útrata R, Loyka S et al.: Post-mortem sperm retrieval in new European Union countries: case report. *Hum Reprod Oxf Engl* 2005; 20(8): 2359-2361.
60. Pilka L, Rumpík D, Pilka R: Dárcovství oocytů: etické a praktické otázky. [Oocyte donation: ethical and practical questions]. *Čes Gynkol* 2003; 68(2): 122-124.

61. Subak LL, Adamson GD, Boltz NL: Therapeutic donor insemination: a prospective randomized trial of fresh versus frozen sperm. *Am J Obstet Gynecol* 1992; 166(6): 1597-1604.
62. DiMarzo SJ, Huang J, Kennedy JF et al.: Pregnancy rates with fresh versus computer-controlled cryopreserved semen for artificial insemination by donor in a private practice setting. *Am J Obstet Gynecol* 1990; 162(6): 1483-1488.
63. Keel BA, Webster BW: Semen analysis data from fresh and cryopreserved donor ejaculates: comparison of cryoprotectants and pregnancy rates. *Fertil Steril* 1989; 52(1): 100-105.
64. Heuchel V, Schwartz D, Czyglik F: Between and within subject correlations and variances for certain semen characteristics in fertile men. *Andrologia* 1983; 15(2): 171-176.
65. Anger JT, Gilbert BR, Goldstein M: Cryopreservation of sperm: indications, methods and results. *J Urol* 2003; 170(4): 1079-1084.
66. Rivkees SA, Crawford JD: The relationship of gonadal activity and chemotherapy-induced gonadal damage. *JAMA* 1988; 259(14): 2123-2125.
67. Ward JA, Robinson J, Furr BJ et al.: Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist. *Cancer Res* 1990; 50(3): 568-574.
68. Meistrich ML, Wilson G, Huhtaniemi I: Hormonal treatment after cytotoxic therapy stimulates recovery of spermatogenesis. *Cancer Res* 1999; 59(15): 3557-3560.
69. Meistrich ML, Wilson G, Kangasniemi M, Huhtaniemi I: Mechanism of protection of rat spermatogenesis by hormonal pretreatment: stimulation of spermatogonial differentiation after irradiation. *J Androl* 2000; 21(3): 464-469.
70. Thomson AB, Anderson RA, Irvine DS et al.: Investigation of suppression of the hypothalamic-pituitary-gonadal axis to restore spermatogenesis in azoospermic men treated for childhood cancer. *Hum Reprod Oxf Engl* 2002; 17(7): 1715-1723.
71. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. *CA Cancer J Clin* 2000; 50(1): 7-33.
72. Ventruba P, Žáková J, Adler J a kol.: Prodloužená kultivace lidských embryí: srovnání kokultivace na lidských tubárních epiteliích a kultivace v syntetickém médiu [Prolonged culture of human embryos: comparison of coculture on human tubal epithelium and culture in synthetic media]. *Čes Gynecol* 1996; 61(6): 351-357.
73. Ventruba P, Mardešić T, Pilka L a kol.: Národní registr asistované reprodukce: výsledky a analýza komplikací [The National Register for Assisted Reproduction: results and analysis of complications]. *Čes Gynecol* 1998; 63(2): 107-110.
74. Oktay K, Hourvitz A, Sahin G et al.: Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. *J Clin Endocrinol Metab* 2006; 91(10): 3885-3890.
75. Requena A et al.; Reproductive Endocrinology Interest Group of Spanish Society of Fertility: Use of letrozole in assisted reproduction: a systematic review and meta-analysis. *Hum Reprod Update* 2008; 14(6): 571-582.
76. Pritts EA: Letrozole for ovulation induction and controlled ovarian hyperstimulation. *Curr Opin Obstet Gynecol* 2010; 22(4): 289-294.
77. Bedoschi G, Oktay K: Current approach to fertility preservation by embryo cryopreservation. *Fertil Steril* 2013; 99(6): 1496-1502.
78. Fahy GM, MacFarlane DR, Angell CA, Meryman HT: Vitrification as an approach to cryopreservation. *Cryobiology* 1984; 21(4): 407-426.
79. Hirsh AG: Vitrification in plants as a natural form of cryoprotection. *Cryobiology* 1987; 24(3): 214-228.

80. Rezazadeh Valojerdi M, Eftekhari-Yazdi P, Karimian L et al.: Vitrification versus slow freezing gives excellent survival, post warming embryo morphology and pregnancy outcomes for human cleaved embryos. *J Assist Reprod Genet* 2009; 26(6): 347-354.
81. Fasano C, Fontenelle N, Vannin AS et al.: A randomized controlled trial comparing two vitrification methods versus slow-freezing for cryopreservation of human cleavage stage embryos. *J Assist Reprod Genet* 2013; 31(2): 241-247.
82. Boiso I, Martí M, Santaló J et al.: A confocal microscopy analysis of the spindle and chromosome configurations of human oocytes cryopreserved at the germinal vesicle and metaphase II stage. *Hum Reprod Oxf Engl* 2002; 17(7): 1885-1891.
83. Tao T, Del Valle A: Human oocyte and ovarian tissue cryopreservation and its application. *J Assist Reprod Genet* 2008; 25(7): 287-296.
84. Katayama KP, Stehlik J, Kuwayama M et al.: High survival rate of vitrified human oocytes results in clinical pregnancy. *Fertil Steril* 2003; 80(1): 223-224.
85. Cobo A, Bellver J, Domingo J et al.: New options in assisted reproduction technology: the Cryotop method of oocyte vitrification. *Reprod Biomed Online* 2008; 17(1): 68-72.
86. Chian RC, Huang JY, Tan SL et al.: Obstetric and perinatal outcome in 200 infants conceived from vitrified oocytes. *Reprod Biomed Online* 2008; 16(5): 608-610.
87. Ciotti PM, Porcu E, Notarangelo L et al.: Meiotic spindle recovery is faster in vitrification of human oocytes compared to slow freezing. *Fertil Steril* 2009; 91(6): 2399-2407.
88. Porcu E, Bazzocchi A, Notarangelo L et al.: Human oocyte cryopreservation in infertility and oncology. *Curr Opin Endocrinol Diabetes Obes* 2008; 15(6): 529-535.
89. Huser M, Crha I, Žáková J, Ventruba P: Onkofertilita - nový směr reprodukční medicíny [Oncofertility - a new trend in reproductive medicine]. *Čes Gynekol* 2011; 76(2): 91-99.
90. Demeestere I, Simon P, Buxant F et al.: Ovarian function and spontaneous pregnancy after combined heterotopic and orthotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation: case report. *Hum Reprod Oxf Engl* 2006; 21(8): 2010-2014.
91. Rosendahl M, Greve T, Andersen CY: The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. *J Assist Reprod Genet* 2013; 30(1): 11-24.
92. Donnez J, Dolmans MM, Demylle D et al.: Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. *Lancet* 2004; 364(9443): 1405-1410.
93. Hovatta O: Methods for cryopreservation of human ovarian tissue. *Reprod Biomed Online* 2005; 10(6): 729-734.
94. Newton H, Aubard Y, Rutherford A et al.: Low temperature storage and grafting of human ovarian tissue. *Hum Reprod Oxf Engl* 1996; 11(7): 1487-1491.
95. Martinez-Madrid B, Dolmans MM, Van Langendonck A et al.: Freeze-thawing intact human ovary with its vascular pedicle with a passive cooling device. *Fertil Steril* 2004; 82(5): 1390-1394.
96. Imhof M, Bergmeister H, Lipovac M et al.: Orthotopic microvascular reanastomosis of whole cryopreserved ovine ovaries resulting in pregnancy and live birth. *Fertil Steril* 2006; 85, suppl. 1: 1208-1215.
97. Xu M, Barrett SL, West-Farrell E et al.: In vitro grown human ovarian follicles from cancer patients support oocyte growth. *Hum Reprod Oxf Engl* 2009; 24(10): 2531-2540.
98. Gook DA, Edgar DH, Borg J et al.: Diagnostic assessment of the developmental potential of human cryopreserved ovarian tissue from multiple patients using xenografting. *Hum Reprod Oxf Engl* 2005; 20(1): 72-78.
99. Isachenko V, Isachenko E, Reinsberg J et al.: Cryopreservation of human ovarian tissue: effect of spontaneous and initiated ice formation. *Reprod Biomed Online* 2008; 16(3): 336-345.

100. Revel A, Revel-Vilk S, Aizenman E et al.: At what age can human oocytes be obtained? *Fertil Steril* 2009; 92(2): 458-463.
101. Baird DT, Webb R, Campbell BK et al.: Long-term ovarian function in sheep after ovariectomy and transplantation of autografts stored at -196 C. *Endocrinology* 1999; 140(1): 462-471.
102. Nisolle M, Casanas-Roux F, Qu J et al.: Histologic and ultrastructural evaluation of fresh and frozen-thawed human ovarian xenografts in nude mice. *Fertil Steril* 2000; 74(1): 122-129.
103. Kim SS: Assessment of long term endocrine function after transplantation of frozen-thawed human ovarian tissue to the heterotopic site: 10 year longitudinal follow-up study. *J Assist Reprod Genet* 2012; 29(6): 489-493.
104. Bedaiwy MA, El-Nashar SA, El Saman AM et al.: Reproductive outcome after transplantation of ovarian tissue: a systematic review. *Hum Reprod Oxf Engl* 2008; 23(12): 2709-2717.
105. Ethics Committee of the American Society for Reproductive Medicine: Fertility preservation and reproduction in cancer patients. *Fertil Steril* 2005; 83(6): 1622-1628.
106. Rodriguez-Wallberg KA, Oktay K: Fertility preservation during cancer treatment: clinical guidelines. *Cancer Manag Res* 2014; 6: 105-117.
107. Jin X, Xiao LJ, Zhang XS, Liu YX: Apoptosis in ovary. *Front Biosci (Schol Ed)* 2011; 3: 680-697.
108. Metallinou C, Asimakopoulos B, Schröer A, Nikolettos N: Gonadotropin-releasing hormone in the ovary. *Reprod Sci Thousand Oaks Calif* 2007; 14(8): 737-749.
109. Huser M, Juránková E, Crha I et al.: Fertility preservation strategies in women undergoing chemotherapy for haematological malignancy. *Eur Clin Obstet Gynaecol* 2006; 2(2): 77-81.
110. Meirou D, Assad G, Dor J, Rabinovici J: The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. *Hum Reprod Oxf Engl* 2004; 19(6): 1294-1299.
111. Falcone T, Bedaiwy MA: Fertility preservation and pregnancy outcome after malignancy. *Curr Opin Obstet Gynecol* 2005; 17(1): 21-26.
112. Meduri G, Touraine P, Beau I et al.: Delayed puberty and primary amenorrhea associated with a novel mutation of the human follicle-stimulating hormone receptor: clinical, histological, and molecular studies. *J Clin Endocrinol Metab* 2003; 88(8): 3491-3498.
113. Hancke K, Strauch O, Kissel C et al.: Sphingosine 1-phosphate protects ovaries from chemotherapy-induced damage in vivo. *Fertil Steril* 2007; 87(1): 172-177.
114. Johnson J, Bagley J, Tilly JL et al.: Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood. *Cell* 2005; 122(2): 303-315.
115. Ataya K, Rao LV, Lawrence E, Kimmel R: Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. *Biol Reprod* 1995; 52(2): 365-372.
116. Del Mastro L, Boni L, Michelotti A et al.: Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. *JAMA* 2011; 306(3): 269-276.
117. Demeestere I, Brice P, Peccatori FA et al.: Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. *J Clin Oncol* 2013; 31(7): 903-909.

118. Bedaiwy MA, Abou-Setta AM, Desai N et al.: Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. *Fertil Steril* 2011; 95(3): 906–914.
119. Badawy A, Elnashar A, El-Ashry M, Shahat M: Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. *Fertil Steril* 2009; 91(3): 694–697.
120. Blumenfeld Z, Avivi I, Eckman A et al.: Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. *Fertil Steril* 2008; 89(1): 166–173.
121. Huser M, Crha I, Ventruba P et al.: Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. *Hum Reprod Oxf Engl* 2008; 23(4): 863–868.
122. Chen H, Li J, Cui T, Hu L: Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. *Cochrane Database Syst Rev* 2011; 11: CD008018.
123. Zhang Y, Xiao Z, Wang Y et al.: Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients. *PloS One* 2013; 8(11): e80444.
124. Wang C, Chen M, Fu F, Huang M: Gonadotropin-releasing hormone analog cotreatment for the preservation of ovarian function during gonadotoxic chemotherapy for breast cancer: a meta-analysis. *PloS One* 2013; 8(6): e66360.
125. Huser M: Možnosti ochrany reprodukčních funkcí u žen podstupujících chemoterapii pro hematologickou malignitu. *Závěrečná zpráva o řešení programového projektu podpořeného Interní grantovou agenturou Ministerstva zdravotnictví ČR*, 2008.
126. Mardešić T, Šnajderová M, Šrámková L et al.: Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy. *Eur J Gynaecol Oncol* 2004; 25(1): 90–92.
127. Huser M: Ochrana reprodukčních orgánů a funkcí u žen podstupujících protinádorovou léčbu. *Disertační práce. Lékařská fakulta Masarykovy Univerzity v Brně*, 2008.
128. Huser M, Žáková J, Šmardová L et al.: Combination of fertility preservation strategies in young women with recently diagnosed cancer. *Eur J Gynaecol Oncol* 2012; 33(1): 42–50.
129. Dursun P, Ayhan A, Yanik FB, Kuşçu E: Ovarian transposition for the preservation of ovarian function in young patients with cervical carcinoma. *Eur J Gynaecol Oncol* 2009; 30(1): 13–15.
130. Hwang JH, Yoo HJ, Park SH et al.: Association between the location of transposed ovary and ovarian function in patients with uterine cervical cancer treated with (postoperative or primary) pelvic radiotherapy. *Fertil Steril* 2012; 97(6): 1387–1393.
131. Ventruba P, Pilka L, Cupr Z et al.: Oocyte removal in conjunction with pelvic microsurgery. *Zentralblatt Für Gynäkol* 1991; 113(10): 557–561.
132. Pilka L, Rumpík D, Pilka R a kol.: Surogátní mateřství – literární názory a praxe. [Surrogate maternity – literature review and practice]. *Čes Gynkol* 2009; 74(2): 144–147.
133. Loren AW, Mangu PB, Beck LN et al.: Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 2013; 31(19): 2500–2510.
134. Wallace WH, Anderson RA, Irvine DS: Fertility preservation for young patients with cancer: who is at risk and what can be offered? *Lancet Oncol* 2005; 6(4): 209–218; erratum in: *Lancet Oncol* 2005; 6(12): 922.

135. Backhus LE, Kondapalli LA, Chang RJ et al.: Oncofertility consortium consensus statement: guidelines for ovarian tissue cryopreservation. *Cancer Treat Res* 2007; 138: 235-239.
136. Ethics Committee of American Society for Reproductive Medicine: Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. *Fertil Steril* 2013; 100(5): 1224-1231.
137. Robison LL et al.: The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. *J Clin Oncol* 2009; 27(14): 2308-2318.
138. Huser V, Narus SP, Rocha RA: Evaluation of a flowchart-based EHR query system: a case study of RetroGuide. *J Biomed Inform* 2010; 43(1): 41-50.
139. Barekati Z, Gourabi H, Valojerdi MR, Yazdi PE: Previous maternal chemotherapy by cyclophosphamide (Cp) causes numerical chromosome abnormalities in pre-implantation mouse embryos. *Reprod Toxicol* 2008; 26(3-4): 278-281.
140. Vital-Reyes V, Tellez-Velasco S, Chhieng D et al.: Spontaneous pregnancy in a woman with premature ovarian failure: a case report. *J Reprod Med* 2004; 49(12): 989-991